World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
101
Citations
58243
World Ranking
688
National Ranking
397

Medicine

D-Index
101
Citations
58370
World Ranking
7806
National Ranking
4071

Diane V. Havlir publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Diane V. Havlir sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 538 publications — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Diane V. Havlir D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Diane V. Havlir sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 101 D-Index — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2019 - Member of the National Academy of Medicine (NAM)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Diane V. Havlir is affiliated with the University of California, San Francisco in the United States. Their main field of study is Medicine, with a particular focus on Infectious Diseases and related subfields including Epidemiology, General Health Professions, Virology, and Pediatrics, Perinatology, and Child Health.

The scientist has contributed extensively to several main research topics, such as:

  • HIV/AIDS Research and Interventions
  • HIV, Drug Use, Sexual Risk
  • SARS-CoV-2 and COVID-19 Research
  • HIV Research and Treatment
  • SARS-CoV-2 detection and testing
  • Adolescent Sexual and Reproductive Health
  • HIV/AIDS drug development and treatment

Recent publications by Diane V. Havlir include:

  • Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19, 2020, New England Journal of Medicine
  • Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections, 2023, New England Journal of Medicine
  • Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19, 2021, Science Translational Medicine
  • Performance Characteristics of a Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Antigen Detection Assay at a Public Plaza Testing Site in San Francisco, 2020, The Journal of Infectious Diseases
  • Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study, 2020, The Lancet HIV

The scientist frequently collaborates with several other researchers, including Moses R. Kamya, Gabriel Chamie, Jane Kabami, James Ayieko, and Maya Petersen.

Diane V. Havlir's work appears regularly in multiple publication venues, demonstrating breadth in dissemination of research. Some frequent publication venues include:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Journal of the International AIDS Society
  • UNC Libraries
  • Clinical Infectious Diseases
  • PLoS ONE

Recognition of Diane V. Havlir's contributions to the medical field includes membership in distinguished organizations such as the National Academy of Medicine (NAM) since 2019 and the Association of American Physicians.

Best Publications

  • Prevention of HIV-1 Infection with Early Antiretroviral Therapy

    Myron S. Cohen;Ying Q. Chen;Marybeth McCauley;Theresa Gamble

  • Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

    Joseph K. Wong;Marjan Hezareh;Huldrych F. Günthard;Diane V. Havlir

  • Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy

    R M Gulick;J W Mellors;D Havlir;J J Eron

  • The end of AIDS: HIV infection as a chronic disease

    Steven G Deeks;Sharon Ruth Lewin;Sharon Ruth Lewin;Diane V Havlir

  • Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections.

    Victor Appay;P. Rod Dunbar;Margaret Callan;Paul Klenerman

  • Antiretroviral Therapy for the Prevention of HIV-1 Transmission

    Myron S. Cohen;Ying Q. Chen;Marybeth McCauley;Theresa Gamble

  • Tuberculosis in Patients with Human Immunodeficiency Virus Infection

    Diane V. Havlir;Peter F. Barnes

  • Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19.

    Monica Gandhi;Deborah S. Yokoe;Diane V. Havlir

  • HIV-Specific Cd8+T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function

    Victor Appay;Douglas F. Nixon;Sean M. Donahoe;Geraldine M.A. Gillespie

  • Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells.

    Z. Q. Zhang;T. Schuler;M. Zupancic;Stephen W Wietgrefe

  • Class-Sparing Regimens for Initial Treatment of HIV-1 Infection

    Sharon A. Riddler;Richard Haubrich;A. Gregory DiRienzo;Lynne Peeples

  • Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.

    D D Richman;D Havlir;J Corbeil;D Looney

  • Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis

    Diane V. Havlir;Michelle A. Kendall;Prudence Ive;Johnstone Kumwenda

  • Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial

    Beatriz Grinsztejn;Mina C. Hosseinipour;Heather J. Ribaudo;Susan Swindells

  • Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission

    Linda Gail Bekker;Linda Gail Bekker;George Alleyne;Stefan Baral;Javier Cepeda

  • Prevalence and predictive value of intermittent viremia with combination hiv therapy.

    Diane V. Havlir;Roland Bassett;Diane Levitan;Peter Gilbert

  • Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections.

    Unknown

  • Prophylaxis against Disseminated Mycobacterium avium Complex with Weekly Azithromycin, Daily Rifabutin, or Both

    Diane V. Havlir;Michael P. Dubé;Fred R. Sattler;Donald N. Forthal

  • Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial

    Richard T. D'Aquila;Michael D. Hughes;Victoria A. Johnson;Margaret A. Fischl

  • Viral Dynamics of Acute HIV-1 Infection

    Susan J. Little;Angela R. McLean;Celsa A. Spina;Celsa A. Spina;Douglas D. Richman;Douglas D. Richman

  • High-Dose Nevirapine: Safety, Pharmacokinetics, And Antiviral Effect In Patients With Human Immunodeficiency Virus Infection

    Diane Havlir;Sarah H. Cheeseman;Margaret Mclaughlin;Robert Murphy

Frequent Co-Authors

Edwin D. Charlebois
Edwin D. Charlebois University of California, San Francisco
Moses R. Kamya
Moses R. Kamya Makerere University
Douglas D. Richman
Douglas D. Richman University of California, San Diego
Grant Dorsey
Grant Dorsey University of California, San Francisco
Joseph K. Wong
Joseph K. Wong University of California, San Francisco
Elizabeth A. Bukusi
Elizabeth A. Bukusi University of Washington
Philip J. Rosenthal
Philip J. Rosenthal University of California, San Francisco
Harsha Thirumurthy
Harsha Thirumurthy University of Pennsylvania
Judith S. Currier
Judith S. Currier University of California, Los Angeles
Huldrych F. Günthard
Huldrych F. Günthard University of Zurich

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those studying Immunology in the USA, exploring related healthcare degrees can expand career opportunities. Many professionals pursue advanced nursing roles, which complement immunological knowledge, especially in patient care and clinical settings.

One popular route is transitioning to an Acute Care Nurse Practitioner (NP) role. Obtaining an acute care np certification allows nurses to specialize in treating patients with complex, critical conditions, often involving immunological issues.

To fast-track this process, students can consider accelerated np programs, which offer intensive curricula designed to prepare students for licensure swiftly while balancing other commitments.

For those without a nursing background, enrolling in online absn programs for non nurses offers a flexible pathway into nursing, building foundational skills to support a future in immunology and healthcare.

Understanding potential earnings is also vital. Resources covering dnp salary transparency provide valuable insights into compensation across states, helping inform career decisions after degree completion.

Best Scientists Citing Diane V. Havlir

Trending Scientists

Recently Published Articles